Abstract
Objectives Takayasu arteritis (TAK), is a rare autoimmune rheumatic disease causing large vessel vasculitis. Onset is typically between the ages of 20-30. It is associated with substantial morbidity and mortality, notably due to its effects on the cardiovascular system. It has a poorly understood global epidemiology. Our objective was to systematically review the available evidence in order to calculate the incidence rate of TAK.
Methods Three databases (Medline, PubMed and Embase) were searched in November 2019 and the results were screened by two reviewers. A random effects meta-analysis was then conducted in R to calculate the overall incidence rate. Heterogeneity was assessed using I2. The quality of the studies was assessed using an adapted Newcastle-Ottawa scale. Further sub-group analyses were performed by quality, sex, research setting and geographical location. Publication bias was assessed using a Begg’s funnel plot.
Results The incidence rate for TAK per million person-years with 95% confidence intervals was 1.11 per million person years (95% CI 0.75 – 1.65). The heterogeneity in the data was extremely high in all analyses, which suggests that there was considerable variation in incidence rates across the different populations studied. TAK was found to be more common in women (incidence rate 2.01 per million person-years, 95% CI 1.39-2.90).
Conclusions TAK is an extremely rare disease. It affects women more commonly than men. There is considerable variation in the incidence rate between populations. We suggest that future research should focus on discrete populations in order to better identify genetic and environmental risk factors.
Competing Interest Statement
Competing Interest Statement: FP and PCL are recipients of a grant from Vifor pharma. Vifor pharma had no influence on the design, conduct or interpretation of this study. Funding Statement: MR is funded by Vasculitis UK (patient charity). FP and PCL are recipients of a grant from Vifor pharma. Vifor pharma had no influence on the design, conduct or interpretation of this study.
Clinical Trial
PROSPERO registration number CRD42019138795
Funding Statement
Funding Statement: MR is funded by Vasculitis UK (patient charity). FP and PCL are recipients of a grant from Vifor pharma. Vifor pharma had no influence on the design, conduct or interpretation of this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The method for this systematic review was guided by the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement for systematic reviews. The study protocol was registered on PROSPERO on 9th December 2019 with registration number CRD42019138795.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing Interest Statement: FP and PCL are recipients of a grant from Vifor pharma. Vifor pharma had no influence on the design, conduct or interpretation of this study.
Funding Statement: MR is funded by Vasculitis UK (patient charity). FP and PCL are recipients of a grant from Vifor pharma. Vifor pharma had no influence on the design, conduct or interpretation of this study.
Data Availability
Data are available upon reasonable request
